Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CHL028
MIFTS: 59

Childhood Type Dermatomyositis

Categories: Blood diseases, Bone diseases, Muscle diseases, Nephrological diseases, Neuronal diseases, Rare diseases, Respiratory diseases, Skin diseases
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Childhood Type Dermatomyositis

About this section

MalaCards integrated aliases for Childhood Type Dermatomyositis:

Name: Childhood Type Dermatomyositis 39 12 15
Juvenile Dermatomyositis 12 77 54 60 17 74
Dermatomyositis, Childhood Type 74
Childhood Dermatomyositis 12
Juvenile Myositis 54
Juvenile Dm 60
Jdm 54
Jpm 54

Characteristics:

Orphanet epidemiological data:

60
juvenile dermatomyositis
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Worldwide); Age of onset: Adolescent,Childhood,Infancy; Age of death: normal life expectancy;

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Neuronal diseases Nephrological diseases Respiratory diseases Bone diseases Skin diseases Muscle diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 34 35
Orphanet: 60  
Rare neurological diseases
Rare renal diseases
Rare respiratory diseases
Rare systemic and rhumatological diseases
Rare skin diseases


Sources

Summaries for Childhood Type Dermatomyositis

About this section
NIH Rare Diseases : 54 Juvenile dermatomyositis has some similarities to adult dermatomyositis and polymyositis. It typically affects children ages 2 to 15 years, with symptoms that include weakness of the muscles close to the trunk of the body, inflammation, edema, muscle pain, fatigue, skin rashes, abdominal pain, fever, and contractures. Children with juvenile dermatomyositis may have difficulty swallowing and breathing, and the heart may also be affected.  About 20 to 30 percent of children with juvenile dermatomyositis develop calcium deposits in the soft tissue. Affected children may not show higher than normal levels of the muscle enzyme creatine kinase in their blood but have higher than normal levels of other muscle enzymes. Treatment is aimed at addressing the individual symptoms of each patient. This may involve a combination of medications, physical therapy and supplements.

MalaCards based summary : Childhood Type Dermatomyositis, also known as juvenile dermatomyositis, is related to myositis and celiac disease 1. An important gene associated with Childhood Type Dermatomyositis is IFIH1 (Interferon Induced With Helicase C Domain 1). The drugs Abatacept and Immunologic Factors have been mentioned in the context of this disorder. Affiliated tissues include skeletal muscle, skin and heart, and related phenotypes are muscle weakness and fatigue

Wikipedia : 77 Juvenile dermatomyositis (JDM) is an idiopathic inflammatory myopathy (IMM) of presumed autoimmune... more...

Sources

Related Diseases for Childhood Type Dermatomyositis

About this section

Diseases related to Childhood Type Dermatomyositis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 105)
# Related Disease Score Top Affiliating Genes
1 myositis 30.5 IFIH1 NT5C1A TRIM21
2 celiac disease 1 29.7 HLA-DQA1 TNFRSF25
3 arthritis 10.4
4 juvenile overlap myositis 10.4
5 dermatomyositis 10.4
6 lung disease 10.3
7 interstitial lung disease 10.3
8 systemic lupus erythematosus 10.2
9 lupus erythematosus 10.2
10 juvenile rheumatoid arthritis 10.2
11 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 10.2
12 panniculitis 10.2
13 vasculitis 10.2
14 idiopathic inflammatory myopathy 10.2
15 adie pupil 10.1 TNFRSF25 TRIM21
16 neonatal lupus erythematosus 10.1 HLA-DQA1 TRIM21
17 autoimmune disease of gastrointestinal tract 10.1 HLA-DQA1 TNFRSF25
18 heart block, congenital 10.1 TNFRSF25 TRIM21
19 enthesopathy 10.1
20 calcinosis 10.1
21 diffuse scleroderma 10.1 TNFRSF25 TRIM21
22 punctate epithelial keratoconjunctivitis 10.1 TNFRSF25 TRIM21
23 type 1 diabetes mellitus 17 10.0 TNFRSF25 VWF
24 rheumatoid arthritis 10.0
25 systemic scleroderma 10.0
26 hypertrichosis 10.0
27 pneumonia 10.0
28 psoriasis 10.0
29 macrophage activation syndrome 10.0
30 autoimmune disease of musculoskeletal system 10.0 TNFRSF25 TRIM21
31 chilblain lupus 1 10.0 IFIH1 TNFRSF25 TRIM21
32 polymyositis 10.0
33 autoimmune disease 9.9
34 skin disease 9.9
35 lymphoma 9.9
36 capillary leak syndrome 9.9
37 rheumatic disease 9.9
38 melanoma 9.9
39 dermatitis 9.9
40 systemic capillary leak syndrome 9.9
41 takayasu arteritis 9.8 HLA-DQA1 VWF
42 blood group, colton system 9.8
43 inclusion body myositis 9.8
44 lipodystrophy, familial partial, type 2 9.8
45 nevus, epidermal 9.8
46 digeorge syndrome 9.8
47 sjogren syndrome 9.8
48 muscular dystrophy, duchenne type 9.8
49 psoriasis 7 9.8
50 autoimmune disease 1 9.8

Graphical network of the top 20 diseases related to Childhood Type Dermatomyositis:



Diseases related to Childhood Type Dermatomyositis
Sources

Symptoms & Phenotypes for Childhood Type Dermatomyositis

About this section

Human phenotypes related to Childhood Type Dermatomyositis:

60 33 (show all 47)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 muscle weakness 60 33 hallmark (90%) Very frequent (99-80%) HP:0001324
2 fatigue 60 33 hallmark (90%) Very frequent (99-80%) HP:0012378
3 dry skin 60 33 hallmark (90%) Very frequent (99-80%) HP:0000958
4 autoimmunity 60 33 hallmark (90%) Very frequent (99-80%) HP:0002960
5 myalgia 60 33 hallmark (90%) Very frequent (99-80%) HP:0003326
6 palpebral edema 60 33 hallmark (90%) Very frequent (99-80%) HP:0100540
7 mucosal telangiectasiae 60 33 hallmark (90%) Very frequent (99-80%) HP:0100579
8 telangiectasia of the skin 60 33 hallmark (90%) Very frequent (99-80%) HP:0100585
9 erythema 60 33 hallmark (90%) Very frequent (99-80%) HP:0010783
10 skin rash 60 33 hallmark (90%) Very frequent (99-80%) HP:0000988
11 elevated c-reactive protein level 60 33 hallmark (90%) Very frequent (99-80%) HP:0011227
12 myositis 60 33 hallmark (90%) Very frequent (99-80%) HP:0100614
13 elevated erythrocyte sedimentation rate 60 33 hallmark (90%) Very frequent (99-80%) HP:0003565
14 calcinosis 60 33 hallmark (90%) Very frequent (99-80%) HP:0003761
15 elevated serum creatine kinase 33 hallmark (90%) HP:0003236
16 muscular hypotonia 60 33 frequent (33%) Frequent (79-30%) HP:0001252
17 constipation 60 33 frequent (33%) Frequent (79-30%) HP:0002019
18 arthritis 60 33 frequent (33%) Frequent (79-30%) HP:0001369
19 fever 60 33 frequent (33%) Frequent (79-30%) HP:0001945
20 arthralgia 60 33 frequent (33%) Frequent (79-30%) HP:0002829
21 pruritus 60 33 frequent (33%) Frequent (79-30%) HP:0000989
22 alopecia 60 33 frequent (33%) Frequent (79-30%) HP:0001596
23 skin ulcer 60 33 frequent (33%) Frequent (79-30%) HP:0200042
24 vasculitis 60 33 frequent (33%) Frequent (79-30%) HP:0002633
25 cutaneous photosensitivity 60 33 frequent (33%) Frequent (79-30%) HP:0000992
26 restrictive ventilatory defect 60 33 frequent (33%) Frequent (79-30%) HP:0002091
27 poikiloderma 60 33 frequent (33%) Frequent (79-30%) HP:0001029
28 muscle spasm 33 frequent (33%) HP:0003394
29 dysarthria 60 33 occasional (7.5%) Occasional (29-5%) HP:0001260
30 dysphonia 60 33 occasional (7.5%) Occasional (29-5%) HP:0001618
31 dysphagia 60 33 occasional (7.5%) Occasional (29-5%) HP:0002015
32 pulmonary fibrosis 60 33 occasional (7.5%) Occasional (29-5%) HP:0002206
33 dyspnea 60 33 occasional (7.5%) Occasional (29-5%) HP:0002094
34 emg abnormality 60 33 occasional (7.5%) Occasional (29-5%) HP:0003457
35 arrhythmia 60 33 occasional (7.5%) Occasional (29-5%) HP:0011675
36 angina pectoris 60 33 occasional (7.5%) Occasional (29-5%) HP:0001681
37 abdominal pain 60 33 occasional (7.5%) Occasional (29-5%) HP:0002027
38 weight loss 60 33 occasional (7.5%) Occasional (29-5%) HP:0001824
39 limitation of joint mobility 60 33 occasional (7.5%) Occasional (29-5%) HP:0001376
40 cardiomyopathy 60 33 occasional (7.5%) Occasional (29-5%) HP:0001638
41 bundle branch block 60 33 occasional (7.5%) Occasional (29-5%) HP:0011710
42 gastrointestinal hemorrhage 60 33 occasional (7.5%) Occasional (29-5%) HP:0002239
43 pericarditis 60 33 occasional (7.5%) Occasional (29-5%) HP:0001701
44 cough 60 33 occasional (7.5%) Occasional (29-5%) HP:0012735
45 hoarse voice 60 33 occasional (7.5%) Occasional (29-5%) HP:0001609
46 elevated serum creatine phosphokinase 60 Very frequent (99-80%)
47 muscle cramps 60 Frequent (79-30%)
Sources

Drugs & Therapeutics for Childhood Type Dermatomyositis

About this section

Drugs for Childhood Type Dermatomyositis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 65)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Abatacept Approved Phase 4,Phase 3 332348-12-6 10237
2 Immunologic Factors Phase 4,Phase 3,Phase 2,Not Applicable
3 Antirheumatic Agents Phase 4,Phase 3,Phase 2
4 Immunosuppressive Agents Phase 4,Phase 3,Phase 2
5 Hormones Phase 4,Phase 3,Phase 2
6 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
7 Hormone Antagonists Phase 4,Phase 3,Phase 2
8 Vaccines Phase 4,Not Applicable
9 beta-endorphin Phase 4
10 Adrenocorticotropic Hormone Phase 4
11 Melanocyte-Stimulating Hormones Phase 4
12
leucovorin Approved Phase 3,Phase 2 58-05-9 143 6006
13
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
14
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2 83-43-2 6741
15
Methylprednisolone hemisuccinate Approved Phase 3,Phase 2 2921-57-5
16
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
17
Prednisolone phosphate Approved, Vet_approved Phase 3,Phase 2 302-25-0
18
Prednisolone Approved, Vet_approved Phase 3,Phase 2 50-24-8 5755
19
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
20
Prednisone Approved, Vet_approved Phase 3,Phase 2 53-03-2 5865
21
Alendronate Approved Phase 2, Phase 3 66376-36-1, 121268-17-5 2088
22
Etanercept Approved, Investigational Phase 2, Phase 3 185243-69-0
23
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
24
Prednisolone hemisuccinate Experimental Phase 3,Phase 2 2920-86-7
25 Antimetabolites, Antineoplastic Phase 3,Phase 2
26 Antineoplastic Agents, Hormonal Phase 3,Phase 2
27 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
28 Folate Phase 3,Phase 2
29 Antiemetics Phase 3,Phase 2
30 Methylprednisolone Acetate Phase 3,Phase 2
31 Vitamin B9 Phase 3,Phase 2
32 Calcineurin Inhibitors Phase 3
33 glucocorticoids Phase 3,Phase 2
34 Protective Agents Phase 3,Phase 2
35 Folic Acid Antagonists Phase 3,Phase 2
36 Gastrointestinal Agents Phase 3,Phase 2
37 Cyclosporins Phase 3
38 Neuroprotective Agents Phase 3,Phase 2
39 Antifungal Agents Phase 3
40 Dermatologic Agents Phase 3,Phase 2
41 Antimetabolites Phase 3,Phase 2
42 Vitamin B Complex Phase 3,Phase 2
43 Anti-Infective Agents Phase 3,Phase 2
44 Autonomic Agents Phase 3,Phase 2
45 Prednisolone acetate Phase 3,Phase 2
46 Peripheral Nervous System Agents Phase 3,Phase 2
47 Anti-Inflammatory Agents Phase 3,Phase 2
48 Bone Density Conservation Agents Phase 2, Phase 3
49 Anti-Inflammatory Agents, Non-Steroidal Phase 2, Phase 3
50 Analgesics Phase 2, Phase 3

Interventional clinical trials:

(show all 25)
# Name Status NCT ID Phase Drugs
1 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
2 Abatacept in Juvenile Dermatomyositis Recruiting NCT02594735 Phase 4 Abatacept
3 Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis Recruiting NCT02245841 Phase 4 H.P. Acthar Gel
4 Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis Unknown status NCT00323960 Phase 3 3 MPDN pulse + PDN;3 MPDN pulse + PDN + CSA;3 MPDN pulse + PDN + MTX
5 Alendronate Osteoporosis Study Completed NCT00277251 Phase 2, Phase 3 Alendronate
6 Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy Recruiting NCT02971683 Phase 3 Abatacept subcutaneous;Placebo
7 Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis Terminated NCT00035958 Phase 2, Phase 3 Prednisone;Methotrexate;Etanercept
8 Absorption of Corticosteroids in Children With Juvenile Dermatomyositis Completed NCT00004357 Phase 2 Methylprednisolone;Prednisolone
9 Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) Completed NCT00106184 Phase 2 Rituximab;Placebo
10 Topical Sodium Thiosulfate and Fractional Carbon Dioxide Laser in Treating Dermatomyositis Associated Calcinosis Completed NCT01572844 Phase 2 Sodium thiosulfate
11 Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis Recruiting NCT03267277 Phase 2 Sodium Thiosulfate
12 Creatine Supplementation in Pediatric Rheumatology Unknown status NCT01217320 Not Applicable
13 The Effect of Creatine Supplementation on Muscle Function in Childhood Myositis Completed NCT02267005 Not Applicable
14 Studies on Abnormal Bone From Patients With Polyostotic Fibrous Dysplasia and McCune Albright Syndrome Completed NCT00001973
15 The CARRA Registry Completed NCT01697254
16 Steroid-Induced Osteoporosis in the Pediatric Population - Canadian Incidence Study Completed NCT01663129
17 Yellow Fever Vaccine in Patients With Rheumatic Diseases Completed NCT03430388 Not Applicable
18 Juvenile Dermatomyositis Recruiting NCT03433638
19 Incidence and Prevalence of Juvenile Dermatomyositis Recruiting NCT03432455
20 Adult and Juvenile Myositis Recruiting NCT00017914
21 Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID / CAPS, DIRA, CANDLE, SAVI, CRMO, Still's Disease, Behcet's Disease, and Other Undifferentiated Autoinflammatory Diseases) Recruiting NCT00059748
22 Environmental Risk Factors for the Anti-synthetase Syndrome Recruiting NCT01276470
23 Study of Families With Twins or Siblings Discordant for Rheumatic Disorders Recruiting NCT00055055
24 Elastography in Patients With Idiopathic Inflammatory Myopathies Not yet recruiting NCT03897803
25 Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes No longer available NCT01724580 Baricitinib

Search NIH Clinical Center for Childhood Type Dermatomyositis

Sources

Genetic Tests for Childhood Type Dermatomyositis

About this section
Sources

Anatomical Context for Childhood Type Dermatomyositis

About this section

MalaCards organs/tissues related to Childhood Type Dermatomyositis:

42
Skeletal Muscle, Skin, Heart, Lung, Bone, T Cells, Testes
Sources

Publications for Childhood Type Dermatomyositis

About this section

Articles related to Childhood Type Dermatomyositis:

(show top 50) (show all 683)
# Title Authors Year
1
Targeting Tregs in Juvenile Idiopathic Arthritis and Juvenile Dermatomyositis-Insights From Other Diseases. ( 30740105 )
2019
2
Juvenile dermatomyositis with IgA nephropathy: case-based review. ( 30552457 )
2019
3
ASYMPTOMATIC MULTIFOCAL PARACENTRAL ACUTE MIDDLE MACULOPATHY ASSOCIATED WITH JUVENILE DERMATOMYOSITIS: OPTICAL COHERENCE ANGIOGRAPHY FINDINGS. ( 30614926 )
2019
4
French expert opinion for the management of juvenile dermatomyositis. ( 30638764 )
2019
5
Superior Mesenteric Artery Syndrome in a Case of Juvenile Dermatomyositis: A Unique Complication. ( 30664541 )
2019
6
Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis. ( 30690571 )
2019
7
Co-existence of Juvenile dermatomyositis and psoriasis vulgaris with fungal infection: A case report and literature review. ( 30697901 )
2019
8
The Association of Short-term Ultraviolet Radiation Exposure and Disease Severity in Juvenile Dermatomyositis. ( 30714338 )
2019
9
Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis. ( 30715143 )
2019
10
Reply: Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis. ( 30715158 )
2019
11
Galectin-9 and CXCL10 as biomarkers for disease activity in juvenile dermatomyositis: a longitudinal cohort study and multi-cohort validation. ( 30861625 )
2019
12
Juvenile dermatomyositis associated with anti-melanoma differentiation-associated gene 5 antibody positivity without complications of interstitial lung disease during the clinical course: A case report. ( 30869164 )
2019
13
Juvenile Dermatomyositis: A Case Report and Review of Literature. ( 30937233 )
2019
14
Association Between Nailfold Capillary Density and Pulmonary and Cardiac Involvement in Medium to Longstanding Juvenile Dermatomyositis. ( 29953739 )
2019
15
Expression of myxovirus-resistance protein A: a possible marker of muscle disease activity and autoantibody specificities in juvenile dermatomyositis. ( 29770465 )
2019
16
Treatment With Rituximab in Juvenile Dermatomyositis: Effect on Calcinosis. ( 30054253 )
2018
17
Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis. ( 30594206 )
2018
18
A Viral Polymyositis Masquerade: Life-Threatening Case of Juvenile Dermatomyositis Complicated by Systemic Capillary Leak Syndrome. ( 29720802 )
2018
19
Cardiorespiratory fitness in long-term juvenile dermatomyositis: a controlled, cross-sectional study of active/inactive disease. ( 30508195 )
2018
20
Muscle Expression of Type I and Type II Interferons Is Increased in Juvenile Dermatomyositis and Related to Clinical and Histological Features. ( 30552836 )
2018
21
Standardising measures in pediatric rheumatology: the experience of the international consensus dataset for juvenile dermatomyositis. ( 30613608 )
2018
22
Systemic and Tissue Inflammation in Juvenile Dermatomyositis: From Pathogenesis to the Quest for Monitoring Tools. ( 30619311 )
2018
23
Juvenile dermatomyositis: is periodontal disease associated with dyslipidemia? ( 30657104 )
2018
24
CD19+CD24hiCD38hi B Cells Are Expanded in Juvenile Dermatomyositis and Exhibit a Pro-Inflammatory Phenotype After Activation Through Toll-Like Receptor 7 and Interferon-α. ( 29988398 )
2018
25
Features distinguishing clinically amyopathic juvenile dermatomyositis from juvenile dermatomyositis. ( 30016492 )
2018
26
Juvenile dermatomyositis forty years on: Case report. ( 30064892 )
2018
27
Increased Soluble Cytoplasmic Bcl-2 Protein Serum Levels and Expression and Decreased Fas Expression in Lymphocytes and Monocytes in Juvenile Dermatomyositis. ( 30068766 )
2018
28
Clinical significance of subcutaneous fat and fascial involvement in juvenile dermatomyositis. ( 30092673 )
2018
29
Clinical subsets of juvenile dermatomyositis classified by myositis-specific autoantibodies: Experience at a single center in Japan. ( 30092736 )
2018
30
Clinical signs and symptoms in a joint model of four disease activity parameters in juvenile dermatomyositis: a prospective, longitudinal, multicenter cohort study. ( 30111380 )
2018
31
Juvenile dermatomyositis: novel treatment approaches and outcomes. ( 30124602 )
2018
32
Expression of the OAS Gene Family Is Highly Modulated in Subjects Affected by Juvenile Dermatomyositis, Resembling an Immune Response to a dsRNA Virus Infection. ( 30227596 )
2018
33
Periorbital Edema as the Initial Sign of Juvenile Dermatomyositis. ( 30234551 )
2018
34
Update on the clinical management of juvenile dermatomyositis. ( 30308133 )
2018
35
Reply: A child with severe juvenile dermatomyositis treated with ruxolitinib. ( 30335129 )
2018
36
A child with severe juvenile dermatomyositis treated with ruxolitinib. ( 30335130 )
2018
37
Fashionably Late: A Case of Delayed Cutaneous Manifestations in Juvenile Dermatomyositis. ( 30344821 )
2018
38
Serum biomarkers of glucocorticoid response and safety in anti-neutrophil cytoplasmic antibody-associated vasculitis and juvenile dermatomyositis. ( 30352204 )
2018
39
The Vasculopathy of Juvenile Dermatomyositis. ( 30356795 )
2018
40
Pattern of myogenesis and vascular repair in early and advanced lesions of juvenile dermatomyositis. ( 30389421 )
2018
41
Inpatient burden of juvenile dermatomyositis among children in the United States. ( 30424778 )
2018
42
Dysregulated NK cell PLCγ2 signaling and activity in juvenile dermatomyositis. ( 30429375 )
2018
43
Long-term follow-up of autologous hematopoietic stem cell transplantation for refractory juvenile dermatomyositis: a case-series study. ( 30458860 )
2018
44
Efficacy and Safety of Cyclophosphamide Treatment in Severe Juvenile Dermatomyositis Shown by Marginal Structural Modeling. ( 29342499 )
2018
45
Multiple target autoantigens on endothelial cells identified in juvenile dermatomyositis using proteomics. ( 29361142 )
2018
46
Extensive skin ulcers in a child with juvenile dermatomyositis. ( 29367373 )
2018
47
Cardiovascular and cerebrovascular comorbidities of juvenile dermatomyositis in US children: an analysis of the National Inpatient Sample. ( 29373707 )
2018
48
A Bayesian semiparametric Markov regression model for juvenile dermatomyositis. ( 29462840 )
2018
49
Muscle ischaemia associated with NXP2 autoantibodies: a severe subtype of juvenile dermatomyositis. ( 29474663 )
2018
50
Koebner Phenomenon in Juvenile Dermatomyositis. ( 29496916 )
2018
Sources

Variations for Childhood Type Dermatomyositis

About this section
Sources

Expression for Childhood Type Dermatomyositis

About this section
LifeMap Discovery
Genes differentially expressed in tissues of Childhood Type Dermatomyositis patients vs. healthy controls: 35 (show all 35)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 IFIT3 interferon-induced protein with tetratricopeptide repeats 3 Skeletal Muscle + 5.58 0.000
2 ISG15 ISG15 ubiquitin-like modifier Skeletal Muscle + 5.25 0.000
3 XIST X inactive specific transcript (non-protein coding) Skeletal Muscle + 5.14 0.000
4 RSAD2 radical S-adenosyl methionine domain containing 2 Skeletal Muscle + 4.94 0.000
5 GBP1 guanylate binding protein 1, interferon-inducible Skeletal Muscle + 4.88 0.000
6 CMPK2 cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial Skeletal Muscle + 4.61 0.000
7 IFI44L interferon-induced protein 44-like Skeletal Muscle + 4.42 0.000
8 MX1 MX dynamin-like GTPase 1 Skeletal Muscle + 4.40 0.000
9 IFI44 interferon-induced protein 44 Skeletal Muscle + 4.34 0.000
10 IFIT2 interferon-induced protein with tetratricopeptide repeats 2 Skeletal Muscle + 3.96 0.000
11 IFI27 interferon, alpha-inducible protein 27 Skeletal Muscle + 3.86 0.000
12 CXCL11 chemokine (C-X-C motif) ligand 11 Skeletal Muscle + 3.67 0.000
13 RPS4Y1 ribosomal protein S4, Y-linked 1 Skeletal Muscle - 3.57 0.000
14 IFIT1 interferon-induced protein with tetratricopeptide repeats 1 Skeletal Muscle + 3.57 0.000
15 MYH3 myosin, heavy chain 3, skeletal muscle, embryonic Skeletal Muscle + 3.54 0.000
16 SAMHD1 SAM domain and HD domain 1 Skeletal Muscle + 3.52 0.000
17 XAF1 XIAP associated factor 1 Skeletal Muscle + 3.44 0.000
18 KLHDC7B kelch domain containing 7B Skeletal Muscle + 3.44 0.000
19 IFI6 interferon, alpha-inducible protein 6 Skeletal Muscle + 3.43 0.000
20 IFIH1 interferon induced with helicase C domain 1 Skeletal Muscle + 3.43 0.000
21 PARP12 poly (ADP-ribose) polymerase family, member 12 Skeletal Muscle + 3.41 0.000
22 IFI16 interferon, gamma-inducible protein 16 Skeletal Muscle + 3.40 0.000
23 PLSCR1 phospholipid scramblase 1 Skeletal Muscle + 3.37 0.000
24 STAT1 signal transducer and activator of transcription 1, 91kDa Skeletal Muscle + 3.37 0.000
25 PSMB8 proteasome subunit beta 8 Skeletal Muscle + 3.35 0.000
26 NNMT nicotinamide N-methyltransferase Skeletal Muscle + 3.31 0.000
27 TRIM22 tripartite motif containing 22 Skeletal Muscle + 3.27 0.000
28 DTX3L deltex 3 like, E3 ubiquitin ligase Skeletal Muscle + 3.23 0.000
29 EIF2AK2 eukaryotic translation initiation factor 2-alpha kinase 2 Skeletal Muscle + 3.14 0.000
30 IRF7 interferon regulatory factor 7 Skeletal Muscle + 3.13 0.000
31 OAS1 2'-5'-oligoadenylate synthetase 1, 40/46kDa Skeletal Muscle + 3.09 0.000
32 IFITM1 interferon induced transmembrane protein 1 Skeletal Muscle + 3.06 0.000
33 TNFSF10 tumor necrosis factor (ligand) superfamily, member 10 Skeletal Muscle + 3.05 0.000
34 PARP9 poly (ADP-ribose) polymerase family, member 9 Skeletal Muscle + 3.05 0.000
35 POSTN periostin, osteoblast specific factor Skeletal Muscle + 3.03 0.000
Search GEO for disease gene expression data for Childhood Type Dermatomyositis.
Sources

Pathways for Childhood Type Dermatomyositis

About this section
Sources

GO Terms for Childhood Type Dermatomyositis

About this section

Biological processes related to Childhood Type Dermatomyositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 interferon-gamma-mediated signaling pathway GO:0060333 8.62 HLA-DQA1 TRIM21

Molecular functions related to Childhood Type Dermatomyositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 zinc ion binding GO:0008270 9.26 IFIH1 MORC3 SNRPC TRIM21
2 single-stranded RNA binding GO:0003727 8.62 IFIH1 SNRPC
Sources

Sources for Childhood Type Dermatomyositis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....